Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 6, 2026, details material definitive agreements entered into by Catheter Precision, Inc. on March 9, 2026. The Company is undertaking a significant capital restructuring and strategic pivot involving a private placement financing and the acquisition of a new business entity, Fly Flyte, Inc. (FLYTE).
Key Financial Metrics and Transaction Values
- Private Placement Financing:
- Initial Commitment: $1,853,000 for Series C-1 Convertible Preferred Stock (1,853 shares).
- Additional Closings: Agreements to purchase Series C-2 and Series C-3 Preferred Stock, each for $1,853,000 (Total Initial Preferred: $5,559,000).
- Optional Upside: Purchasers may elect to purchase up to an additional $35,559,326 in Series C-4 Preferred Stock.
- Placement Agent Fees: 7.7% cash fee on proceeds exceeding $3,850,000; no fee on the first $3,850,000.
- FLYTE Acquisition Consideration:
- Total Value: $11,554,827.
- Cash Component: $5,776,827 (comprising $776,827 at closing and a $5,000,000 promissory note).
- Equity Component: 5,778 shares of Series D Convertible Preferred Stock (Stated Value: $5,778,000).
- Debt Instrument: $5,000,000 promissory note issued for the acquisition, bearing 0% interest until December 15, 2026, with a default rate of 18% per annum.
Material Changes and Strategic Shifts
The filing represents a material change in the Company's capital structure and business focus:
- Capital Structure: Introduction of multiple new series of convertible preferred stock (Series C-1, C-2, C-3, C-4, and Series D) with complex conversion pricing mechanisms tied to market prices and a "Floor Price Condition" (potentially $0.35).
- Business Pivot: The Company intends to restructure its legacy catheter business, potentially selling medical devices, to resolve legacy liabilities and reduce cash burn.
- Acquisition: The Company will acquire 100% of Fly Flyte, Inc. and Ponderosa Air, LLC, shifting focus away from legacy operations.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds are designated for general corporate purposes, restructuring the legacy business, settling legacy liabilities, and reducing operating expenses to position the Company as a streamlined public entity.
- Stockholder Approval: Conversion of preferred stock into common stock is contingent upon stockholder approval under NYSE American Section 713. A meeting must be held no later than April 10, 2026.
- Registration Rights: The Company must file a registration statement for the resale of underlying common stock within 30 days of the first closing, with effectiveness targeted within 60 days.
- Risks:
- Failure to obtain stockholder approval may prevent the conversion of preferred stock.
- The acquisition is subject to customary closing conditions.
- Significant dilution potential exists due to the convertible nature of the preferred stock and the "floor price" waiver discretion held by the Company.
Investor Verification Checklist
- Verify the status of the stockholder meeting scheduled for no later than April 10, 2026, required for Section 713 approval.
- Confirm the actual closing date and gross proceeds received for the Series C-1, C-2, and C-3 Preferred Stock.
- Review the specific terms of the $5,000,000 promissory note regarding installment dates and default triggers.
- Monitor the filing and effectiveness of the Registration Statement for the resale of underlying common stock.
- Assess the progress of the legacy catheter business restructuring and potential asset sales.